The chemical class of RNF141 Activators encompasses a range of compounds that are designed to modulate the function of RNF141, a member of the RING finger protein family, through indirect mechanisms. RNF141 is involved in the ubiquitin-proteasome system, a critical pathway for protein degradation and turnover in cells. Although direct chemical activators for RNF141 have not been explicitly identified, the proposed activators in this class can influence the protein's activity by altering related cellular processes or signaling pathways. The potential for these compounds to interact with RNF141's function highlights the intricate nature of cellular regulatory mechanisms and the capability of small molecules to influence key biological processes.
Compounds in the RNF141 Activators class may include kinase inhibitors or enhancers, which can modify the phosphorylation status of proteins within the ubiquitination pathway, thereby impacting RNF141's activity. Additionally, this class might contain molecules that affect the proteasome activity or ubiquitin-like processes, crucial for the protein degradation system in which RNF141 is a key player. These compounds could operate by altering ubiquitin availability, changing the expression of proteins involved in the ubiquitination pathway, or affecting the stability and function of proteins that interact with RNF141. By targeting these broader processes and pathways, the compounds classified as RNF141 Activators demonstrate the ability to subtly influence the ubiquitin-proteasome system and the activity of RNF141 within it. This class represents a sophisticated approach to modulating protein function in cellular regulation, underlining the potential of chemical compounds to exert control over complex and interconnected biological systems.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Targets the proteasome, potentially impacting the ubiquitin-proteasome system associated with RNF14 | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Modulates the ubiquitin-proteasome system, which could intersect with RNF141's regulatory mechanisms. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
Similar to Thalidomide, affects the ubiquitin-proteasome system, potentially impacting RNF14 | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $98.00 $140.00 $306.00 $459.00 $1224.00 $1958.00 | 1 | |
Another thalidomide derivative that influences the ubiquitin-proteasome system, potentially affecting RNF14 | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Known to modulate various signaling pathways, potentially impacting the ubiquitin-proteasome system and RNF14 | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Affects gene expression and signaling pathways, possibly intersecting with RNF141's functions. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Influences GSK-3β and Wnt signaling, which may intersect with pathways involving RNF14 |